2021
DOI: 10.1124/jpet.120.000486
|View full text |Cite
|
Sign up to set email alerts
|

A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
23
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 23 publications
(24 citation statements)
references
References 45 publications
1
23
0
Order By: Relevance
“…7 A–D), indicating that CB-5083 is well tolerated and the suppressive effect on PDE6 and retinal function is reversible. Our earlier investigation in WT and VCP R155H/+ mice led to the same conclusion [ 40 ].
Fig.
…”
Section: Resultssupporting
confidence: 74%
See 2 more Smart Citations
“…7 A–D), indicating that CB-5083 is well tolerated and the suppressive effect on PDE6 and retinal function is reversible. Our earlier investigation in WT and VCP R155H/+ mice led to the same conclusion [ 40 ].
Fig.
…”
Section: Resultssupporting
confidence: 74%
“…In rodent models of VCP disease, cytoplasmic accumulation of TDP-43 is observed widely across brain regions [ 24 , 30 , 34 , 38 ]. Even though CB-5083 bioavailability in the brains is one-third of the levels in the circulating blood [ 40 ], we wanted to assess if CB-5083 treatment for 5 months could modulate these important disease phenotypes in VCP R155H/R155H mice. TDP-43 expression in the vehicle-treated VCP R155H/R155H mice at 7 months was not significantly altered in the brain and the spinal cord compared to the wildtype controls (Fig.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…However, these trials were discontinued and terminated due to adverse effects on vision resulting from inhibition of phosphodiesterase-6 (PDE6). Nevertheless, chronic administration of CB-5083 did not cause permanent retinal damage, which suggested a decrease in CB-5083 doses, and the re-evaluation of this compound as a clinical agent might be appropriate [144].…”
Section: Cb-5083mentioning
confidence: 99%
“…Another interesting point pertains to the advances in the discovery of VCP/p97 inhibitors and the resistance mechanisms associated with VCP mutations, as discussed in the third and fourth sections. Although many inhibitors have been developed in recent years, only two phase I clinical trials on CB-5083 (NCT02243917 and NCT02223598) were initiated, but were terminated due to adverse effects on vision [144]. These data indicate that the design of new VCP/p97 inhibitors or derivatives of existing drugs with stronger inhibitory activity represents an interesting challenge.…”
Section: Conclusion and Future Perspectivesmentioning
confidence: 99%